COLOR stands for: COmplex Large-Bore Radial PCI
The COLOR trial aims to investigate whether transradial PCI is associated with less access site related bleeding- and/or vascular complications as compared with transfemoral PCI for complex coronary lesions with large-bore 7 Fr guiding catheters.
The primary endpoint is defined as any BARC bleeding or vascular complication related to the randomised access site (during hospitalisation).
The COLOR trial is an international, multicenter, prospective, randomized clinical trial designed to enroll 388 patients in up to 12 centers in Europe (The Netherlands, Belgium, Germany, United Kingdom and Switzerland).
The first patient was included in the Isala hospital in the Netherlands on March 5th 2019.
The principal investigators are Maarten van Leeuwen, MD, PhD (interventional cardiologist Isala, Zwolle, The Netherlands) and Adel Aminian MD (interventional cardiologist Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium).